Absolutely right Lowed
That's really the rationale behind the 'allcomer' PD-1 status TACTI trials.
Not withstanding dozens of other combo trials with Keytruda.
So what would force their hand to bid/ license efti?
Another suitor? More mature TACTI data? IP cliff coming for Keytruda?
Must add - thought NSCLC - latest ORR % was disappointing (but explained by data combination and different cohort types - age and pre treatments).
Ann: Encouraging Phase II TACTI-002 data reported at SITC 2020, page-9
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |